Lilly's Fogelsville plant wins final land approval in Upper Macungie

Upper Macungie Township's board of supervisors voted unanimously on Sept. 2, 2026, to grant Eli Lilly final land development approval for its manufacturing campus in Fogelsville, Pennsylvania. The same vote approved the project's sewage planning module. Traffic requirements tied to the build-out are part of the approval and bind the company ^[1].

The board acted after hearing the construction logistics plan. Bailey Occhipinti, Lilly's director of entitlements and permitting for the Lehigh Valley project, said the busiest stretch of building will run from the fourth quarter of 2027 into the first quarter of 2029. During that window the site could hold as many as 1,500 workers, roughly 1,200 in the trades and 300 in administrative roles ^[1].

To move those workers, Lilly plans five entrances to the property and a shuttle system linking the site to parking off campus. The company has lined up 600 spaces near Tilghman Street and has identified more in the Windsor office area nearby, Occhipinti told the board. A new traffic signal and widening of Main Street are scheduled for 2027, ahead of the construction surge ^[1].

Supervisors focused on Tilghman Street, Route 100 and adjacent roads. Vice Chairman Sunny Ghai asked whether crews could be shifted away from the heaviest commuting hours. Occhipinti said the project's traffic study covered several intersections and informed how shifts and shuttle schedules were set ^[1]. As a condition of approval, the board folded that study into later development documents, so its mitigation steps are enforceable and the developer must keep working with the township if congestion emerges ^[1].

What the site is for

The Fogelsville campus is a $3.5 billion project, described when it was announced as the largest single economic development deal in Lehigh Valley history and the biggest life sciences investment Pennsylvania has seen ^[2]. Lilly has said it will hire 850 people permanently there, and that the plant is its fourth U.S. manufacturing site announced since February 2025, part of a $50 billion domestic build-out the company began in 2020 ^[2].

Pennsylvania assembled a $100 million incentive package to land the plant: $50 million in tax credits, a $25 million PA SITES infrastructure grant and a $25 million Pennsylvania First grant ^[2]. The company chose the location over more than 300 others it reviewed nationwide ^[2].

The plant is intended for next-generation weight-loss medicines. The one named at the time of the announcement is retatrutide, an investigational triple hormone receptor agonist that is still in clinical trials and is not an approved medicine ^[2].

The two accounts of the project differ on how many construction workers will be there. Township officials were told as many as 1,500 at the peak ^[1]; the earlier announcement cited about 2,000 during build-out ^[2].

Why it matters for patients

Nothing in the approval changes what is in a pharmacy today. The only product tied to the site in these accounts, retatrutide, is not approved for sale, and it has not been disclosed whether Fogelsville will also make any medicine that is already on the market ^[2]. How the plant's eventual output might affect supply or list prices of existing GLP-1 drugs has not been reported.

For an adult taking semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound), coverage, pricing and label information are unaffected by a township land-use vote ^[1][2]. The practical relevance sits further out: added U.S. manufacturing capacity could matter to availability years from now, but that link has not been established.

Timeline

The Main Street widening and traffic signal are planned for 2027 ^[1]. Peak construction is expected to start in late 2027 and run through early 2029 ^[1]. Construction was slated to begin later in 2026, and the facility is expected to be fully operational by 2031 ^[2]. The traffic provisions approved Sept. 2 remain binding on Lilly ^[1].